The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers
1. The median progression free survival for all cancer-types was 2.8 months. 2. Most of the adverse events (AEs) were ...
Tag: EGFR inhibitor
![Metformin treats Fragile X syndrome symptoms in mice [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2017/07/Metformin_500mg_Tablets-350x250.jpg)
Metformin may improve survival for advanced lung adenocarcinoma patients with higher BMI and taking EGFR-TKI therapy
1. The overall progression-free survival (PFS) was 10.54 years. 2. Patients with body mass weight (BMI) ≥ 24 derived greater ...
Adjuvant gefitinib compared to chemotherapy after lung cancer resection did not improve survival
1. The median disease-free survival for gefitinib group and cisplatin/vinorelbine group was 35.9 and 25.1 months, respectively. 2. Patients receiving ...
Lung cancer mortality reduction linked to improvements in targeted therapies
1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded ...
HLA-DRB1*07:01 confirmed as risk factor for lapatinib-induced liver damage
Image: PD 1. HLA-DRB1*07:01 and HLA-DQA1*02:01 are strongly associated with liver injury among patients with HER2+ primary breast cancer taking ...
